SCHEMBL14949335

SCHEMBL14949335

Cc1cccc(Nc2nnc(-c3cccc(Oc4ccnc5ccccc45)c3)o2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KDR P35968 8/20 0.42
▸ FLT1 P17948 3/20 0.42
▸ FLT4 P35916 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ FGFR2 P21802 2/20 0.40
▸ ABCB1 P08183 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949195 0.91 MEN1 (0.48) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949327 0.89 KDR (0.48) KDM4ESMN1; SMN2KDRFLT1PDGFRA
SCHEMBL12336431 0.86 KDR (0.54) KDM4EKDRFLT1GSK3BEGFR
SCHEMBL17658728 0.85 KDM4E (0.44) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949193 0.81 KDR (0.51) SMN1; SMN2NPC1RAB9ATP53MEN1
SCHEMBL14949323 0.81 KDR (0.44) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949389 0.80 EGFR (0.42) KDM4ESMN1; SMN2NPC1RAB9AMEN1
SCHEMBL14949318 0.80 KDR (0.52) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949321 0.79 KDR (0.46) SMN1; SMN2MEN1KMT2AKDRPDGFRA
SCHEMBL14949325 0.78 FLT1 (0.43) KDM4ESMN1; SMN2NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback